Compare LFVN & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFVN | PLRX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.0M | 69.7M |
| IPO Year | 1996 | 2020 |
| Metric | LFVN | PLRX |
|---|---|---|
| Price | $6.22 | $1.08 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 6 |
| Target Price | ★ $7.50 | $2.67 |
| AVG Volume (30 Days) | 33.8K | ★ 360.8K |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.17% | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $203,204,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.34 | N/A |
| P/E Ratio | $15.80 | ★ N/A |
| Revenue Growth | ★ 1.86 | N/A |
| 52 Week Low | $3.90 | $1.02 |
| 52 Week High | $11.71 | $1.95 |
| Indicator | LFVN | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.79 | 45.29 |
| Support Level | $6.26 | $1.02 |
| Resistance Level | $6.51 | $1.37 |
| Average True Range (ATR) | 0.21 | 0.04 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 53.71 | 18.18 |
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of in the United States, Mexico, Canada, Japan, Taiwan, Thailand, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, Austria, Spain, Ireland, Belgium, and Others. The company operates in a single operating segment by selling products directly to customers through an international network of independent consultants that operate in an integrated manner.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.